Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 55.32% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $25.8 million, a 55.32% increase from a year earlier, with the FY2025 full-year figure at $35.6 million, up 23.16% from the prior year.
• Accumulated Expenses retreated to $25.8 million in Q1 2026 per CRNX's latest filing, from $35.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $35.6 million in Q4 2025 and bottomed at $4.5 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $14.8 million (2024), against an average of $17.2 million.
• Across the five-year window, Accumulated Expenses jumped 137.03% in 2024 and climbed 6.97% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $9.1 million in 2022, then jumped by 59.86% to $14.5 million in 2023, then jumped by 98.99% to $28.9 million in 2024, then rose by 23.16% to $35.6 million in 2025, then decreased by 27.51% to $25.8 million in 2026.
• Per Business Quant, the three latest CRNX Accumulated Expenses figures stand at $25.8 million (Q1 2026), $35.6 million (Q4 2025), and $32.4 million (Q3 2025).